Fidelity International’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-1,140,000
| Closed | -$45.9M | – | 1149 |
|
|
2026
Q1 | $45.9M | Buy |
+1,140,000
| New | +$24.6M | 0.04% | 358 |
|
|
2024
Q4 | – | Sell |
-11,467
| Closed | -$331K | – | 917 |
|
|
2024
Q3 | $331K | Buy |
11,467
+380
| +3% | +$14.1K | ﹤0.01% | 812 |
|
|
2024
Q2 | $425K | Buy |
11,087
+4,979
| +82% | +$225K | ﹤0.01% | 767 |
|
|
2024
Q1 | $359K | Buy |
6,108
+431
| +8% | +$27.5K | ﹤0.01% | 778 |
|
|
2023
Q4 | $340K | Buy |
+5,677
| New | +$288K | ﹤0.01% | 747 |
|
|
2021
Q3 | – | Sell |
-309,031
| Closed | -$19.5M | – | 824 |
|
|
2021
Q2 | $19.5M | Buy |
309,031
+1,456
| +0.5% | +$75.1K | 0.02% | 457 |
|
|
2021
Q1 | $13.2M | Sell |
307,575
-11,579
| -4% | -$548K | 0.02% | 486 |
|
|
2020
Q4 | $18.3M | Buy |
319,154
+189,835
| +147% | +$8.03M | 0.02% | 417 |
|
|
2020
Q3 | $3.9M | Sell |
129,319
-850,397
| -87% | -$25.4M | ﹤0.01% | 553 |
|
|
2020
Q2 | $32M | Sell |
979,716
-124,633
| -11% | -$4M | 0.04% | 326 |
|
|
2020
Q1 | $29.6M | Sell |
1,104,349
-289,936
| -21% | -$10.3M | 0.05% | 300 |
|
|
2019
Q4 | $42.7M | Buy |
1,394,285
+297,083
| +27% | +$8.22M | 0.06% | 280 |
|
|
2019
Q3 | $26.4M | Buy |
+1,097,202
| New | +$30.2M | 0.04% | 333 |
|
Other funds holding APLS
Fidelity International's APLS Position: Q2 2026 in Review
Fidelity International sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 1,140,000 shares — an estimated $45.9M sold.
Fidelity International first reported a position in APLS in Q3 2019 and held it in 13 quarters. The position peaked at $45.9M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Fidelity International reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Fidelity International sold 1,140,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $45.9M.
- Fidelity International first reported a position in Apellis Pharmaceuticals in Q3 2019 and held it in 13 quarters.
- Fidelity International's Apellis Pharmaceuticals position peaked at $45.9M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.